{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:35:12Z","timestamp":1790994912131,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T00:00:00Z","timestamp":1558224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T00:00:00Z","timestamp":1558224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG046153"],"award-info":[{"award-number":["AG046153"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG054714"],"award-info":[{"award-number":["AG054714"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI104034"],"award-info":[{"award-number":["AI104034"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008097","name":"Edward N. and Della L. Thome Memorial Foundation","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100008097","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paul F. Glenn Center for Aging At Salk","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s12035-019-1637-8","type":"journal-article","created":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T23:16:54Z","timestamp":1558307814000},"page":"7719-7730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"56","author":[{"given":"David","family":"Schubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Kepchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dargusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0694-0610","authenticated-orcid":false,"given":"Pamela","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,19]]},"reference":[{"key":"1637_CR1","unstructured":"Alzheimer\u2019s Disease International (2015, www.alz.co.uk\/research\/statistics ) Dementia statistics. Vol. 2018, n.p."},{"key":"1637_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/cts.12491","volume":"11","author":"J Cummings","year":"2018","unstructured":"Cummings J (2018) Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin Transl Sci 11:147\u2013152","journal-title":"Clin Transl Sci"},{"key":"1637_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1021\/cn500051h","volume":"5","author":"M Prior","year":"2014","unstructured":"Prior M, Chiruta C, Currais A, Goldberg J, Dargusch R, Maher P, Schubert D (2014) Back to the future with phenotypic screening. ACS Chem Neurosci 5:503\u2013513","journal-title":"ACS Chem Neurosci"},{"key":"1637_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-59259-947-9_2","volume-title":"Marijuana and th cannabinoids (322 pgs)","author":"R Brenneisen","year":"2007","unstructured":"Brenneisen R (2007) Chemistry and analysis of phytocannabinoids and other cannabis constituents. In: Eisohly MA (ed) Marijuana and th cannabinoids (322 pgs). Humana Press, Totowa, New Jersey, pp. 17\u201349"},{"key":"1637_CR5","doi-asserted-by":"publisher","unstructured":"Mastinu A, Premoli M, Ferrari-Toninelli G, Tambaro S, Maccarinelli G, Memo M, Bonini SA (2018) Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Horm Mol Biol Clin Investig. https:\/\/doi.org\/10.1515\/hmbci-2018-0013","DOI":"10.1515\/hmbci-2018-0013"},{"issue":"18","key":"1637_CR6","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.2174\/0929867325666180226095132","volume":"26","author":"Juan A. P\u00e1ez","year":"2019","unstructured":"Paez JA, Campillo NE (2018) Innovative therapeutic potential of cannabinoid receptors as targets in Alzheimer\u2019s disease and less well-known diseases. Curr Med Chem. https:\/\/doi.org\/10.2174\/0929867325666180226095132","journal-title":"Current Medicinal Chemistry"},{"key":"1637_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","volume":"64","author":"R Mechoulam","year":"2013","unstructured":"Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21\u201347","journal-title":"Annu Rev Psychol"},{"key":"1637_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1096\/fj.201601184","volume":"31","author":"A Currais","year":"2017","unstructured":"Currais A, Fischer W, Maher P, Schubert D (2017) Intraneuronal protein aggregation as a trigger for inflammation and neurodegeneration in the aging brain. FASEB J 31:5\u201310","journal-title":"FASEB J"},{"key":"1637_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4161\/auto.5269","volume":"4","author":"A Simonsen","year":"2008","unstructured":"Simonsen A, Cumming RC, Brech A, Isakson P, Schubert DR, Finley KD (2008) Promoting basal levels of autophagy in the nervous system enhances longevity and oxidant resistance in adult drosophila. Autophagy. 4:176\u2013184","journal-title":"Autophagy."},{"key":"1637_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0169-328X(94)90092-2","volume":"26","author":"BL Sopher","year":"1994","unstructured":"Sopher BL, Fukuchi K, Smith AC, Leppig KA, Furlong CE, Martin GM (1994) Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. Brain Res Mol Brain Res 26:207\u2013217","journal-title":"Brain Res Mol Brain Res"},{"key":"1637_CR11","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/sj.cdd.4401646","volume":"12","author":"F Elinder","year":"2005","unstructured":"Elinder F, Akanda N, Tofighi R, Shimizu S, Tsujimoto Y, Orrenius S, Ceccatelli S (2005) Opening of plasma membrane voltage-dependent anion channels (VDAC) precedes caspase activation in neuronal apoptosis induced by toxic stimuli. Cell Death Differ 12:1134\u20131140","journal-title":"Cell Death Differ"},{"key":"1637_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/npjamd.2016.12","volume":"2","author":"A Currais","year":"2016","unstructured":"Currais A, Quehenberger O, A MA, Daugherty D, Maher P, Schubert D (2016) Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. NPJ Aging Mech Dis 2:16012","journal-title":"NPJ Aging Mech Dis"},{"key":"1637_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3233\/JAD-140093","volume":"42","author":"C Cao","year":"2014","unstructured":"Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, Sutherland K, Nabar N et al (2014) The potential therapeutic effects of THC on Alzheimer\u2019s disease. J Alzheimers Dis 42:973\u2013984","journal-title":"J Alzheimers Dis"},{"key":"1637_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-013-9984-x","volume":"34","author":"E Janefjord","year":"2014","unstructured":"Janefjord E, Maag JL, Harvey BS, Smid SD (2014) Cannabinoid effects on beta amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol 34:31\u201342","journal-title":"Cell Mol Neurobiol"},{"key":"1637_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3233\/JAD-160533","volume":"54","author":"E Aso","year":"2016","unstructured":"Aso E, Andres-Benito P, Ferrer I (2016) Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model. J Alzheimers Dis 54:903\u2013912","journal-title":"J Alzheimers Dis"},{"key":"1637_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3233\/JAD-130137","volume":"35","author":"E Aso","year":"2013","unstructured":"Aso E, Juves S, Maldonado R, Ferrer I (2013) CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP\/PS1 mice. J Alzheimers Dis 35:847\u2013858","journal-title":"J Alzheimers Dis"},{"key":"1637_CR17","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.1523\/JNEUROSCI.5183-12.2013","volume":"33","author":"E Valera","year":"2013","unstructured":"Valera E, Dargusch R, Maher PA, Schubert D (2013) Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer\u2019s disease. J Neurosci 33:10512\u201310525","journal-title":"J Neurosci"},{"key":"1637_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.brainres.2007.07.061","volume":"1173","author":"P Maher","year":"2007","unstructured":"Maher P, Salgado KF, Zivin JA, Lapchak PA (2007) A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res 1173:117\u2013125","journal-title":"Brain Res"},{"key":"1637_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ana.410380304","volume":"38","author":"MF Beal","year":"1995","unstructured":"Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357\u2013366","journal-title":"Ann Neurol"},{"key":"1637_CR20","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1089\/ars.2010.3600","volume":"14","author":"J Lewerenz","year":"2011","unstructured":"Lewerenz J, Maher P (2011) Control of redox state and redox signaling by neural antioxidant systems. Antioxid Redox Signal 14:1449\u20131465","journal-title":"Antioxid Redox Signal"},{"key":"1637_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2741\/s425","volume":"7","author":"P Maher","year":"2015","unstructured":"Maher P (2015) How fisetin reduces the impact of age and disease on CNS function. Front Biosci (Schol Ed) 7:58\u201382","journal-title":"Front Biosci (Schol Ed)"},{"key":"1637_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fnins.2018.00214","volume":"12","author":"J Lewerenz","year":"2018","unstructured":"Lewerenz J, Ates G, Methner A, Conrad M, Maher P (2018) Oxytosis\/ferroptosis-(Re-) emerging roles for oxidative stress-dependent non-apoptotic cell death in diseases of the central nervous system. Frontiers Neurosci 12:214","journal-title":"Frontiers Neurosci"},{"key":"1637_CR23","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1523\/JNEUROSCI.21-19-07455.2001","volume":"21","author":"D Schubert","year":"2001","unstructured":"Schubert D, Piasecki D (2001) Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. J Neurosci 21:7455\u20137462","journal-title":"J Neurosci"},{"key":"1637_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fnins.2015.00469","volume":"9","author":"J Lewerenz","year":"2015","unstructured":"Lewerenz J, Chronic MP (2015) Glutamate toxicity in neurodegenerative diseases-what is the evidence? Front Neurosci 9:469","journal-title":"Front Neurosci"},{"key":"1637_CR25","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1248\/bpb.34.1252","volume":"34","author":"S Takeda","year":"2011","unstructured":"Takeda S, Hirayama A, Urata S, Mano N, Fukagawa K, Imamura M, Irii A, Kitajima S et al (2011) Cannabidiol-2\u2032,6\u2032-dimethyl ether as an effective protector of 15-lipoxygenase-mediated low-density lipoprotein oxidation in vitro. Biol Pharm Bull 34:1252\u20131256","journal-title":"Biol Pharm Bull"},{"key":"1637_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12715","volume":"17","author":"J Goldberg","year":"2018","unstructured":"Goldberg J, Currais A, Prior M, Fischer W, Ratiff E, Daugherty D, Dargusch R, Finley K et al (2018) The mitochondrial ATP synthase is a shared drug target among aging and dementia. Aging Cell 17:e12715","journal-title":"Aging Cell"},{"key":"1637_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NKGDNF (2013) NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 138:155\u2013175","journal-title":"Pharmacol Ther"},{"key":"1637_CR28","doi-asserted-by":"publisher","first-page":"5831315","DOI":"10.1155\/2016\/5831315","volume":"2016","author":"KL McCoy","year":"2016","unstructured":"McCoy KL (2016) Interaction between cannabinoid system and toll-like receptors controls inflammation. Mediators Inflamm 2016:5831315","journal-title":"Mediators Inflamm"},{"key":"1637_CR29","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1189\/jlb.0405216","volume":"78","author":"GA Cabral","year":"2005","unstructured":"Cabral GA, Marciano-Cabral F (2005) Cannabinoid receptors in microglia of the central nervous system: Immune functional relevance. J Leukoc Biol 78:1192\u20131197","journal-title":"J Leukoc Biol"},{"key":"1637_CR30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/BF01959156","volume":"44","author":"R Mechoulam","year":"1988","unstructured":"Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TU, Hiltunen AJ, Consroe P (1988) Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia. 44:762\u2013764","journal-title":"Experientia."},{"key":"1637_CR31","first-page":"976","volume":"6","author":"CL Darlington","year":"2003","unstructured":"Darlington CL (2003) Dexanabinol: a novel cannabinoid with neuroprotective properties. IDrugs 6:976\u2013979","journal-title":"IDrugs"},{"key":"1637_CR32","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.neurobiolaging.2006.05.023","volume":"28","author":"T Fukaya","year":"2007","unstructured":"Fukaya T, Gondaira T, Kashiyae Y, Kotani S, Ishikura Y, Fujikawa S, Kiso Y, Sakakibara M (2007) Arachidonic acid preserves hippocampal neuron membrane fluidity in senescent rats. Neurobiol Aging 28:1179\u20131186","journal-title":"Neurobiol Aging"},{"key":"1637_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nature04598","volume":"440","author":"F Darios","year":"2006","unstructured":"Darios F, Davletov B (2006) Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature 440:813\u2013817","journal-title":"Nature"},{"key":"1637_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cbi.2006.08.005","volume":"163","author":"ZJ Wang","year":"2006","unstructured":"Wang ZJ, Liang CL, Li GM, Yu CY, Yin M (2006) Neuroprotective effects of arachidonic acid against oxidative stress on rat hippocampal slices. Chem Biol Interact 163:207\u2013217","journal-title":"Chem Biol Interact"},{"key":"1637_CR35","doi-asserted-by":"publisher","first-page":"831 e821","DOI":"10.1016\/j.neurobiolaging.2011.07.014","volume":"33","author":"Z Amtul","year":"2012","unstructured":"Amtul Z, Uhrig M, Wang L, Rozmahel RF, Beyreuther K (2012) Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer\u2019s disease: structural insight. Neurobiol Aging 33:831 e821\u2013831 e831","journal-title":"Neurobiol Aging"},{"key":"1637_CR36","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/ana.24402","volume":"77","author":"J Sanchez-Ramos","year":"2015","unstructured":"Sanchez-Ramos J (2015) The entourage effect of the phytocannabinoids. Ann Neurol 77:1083","journal-title":"Ann Neurol"},{"key":"1637_CR37","first-page":"1","volume":"103","author":"MA ElSohly","year":"2017","unstructured":"ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A (2017) Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod 103:1\u201336","journal-title":"Prog Chem Org Nat Prod"},{"key":"1637_CR38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.lfs.2005.09.011","volume":"78","author":"MA Elsohly","year":"2005","unstructured":"Elsohly MA, Slade D (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78:539\u2013548","journal-title":"Life Sci"},{"key":"1637_CR39","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2174\/092986710790980050","volume":"17","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17:1360\u20131381","journal-title":"Curr Med Chem"},{"key":"1637_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0306-4522(01)00287-1","volume":"106","author":"N Hajos","year":"2001","unstructured":"Hajos N, Ledent C, Freund TF (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106:1\u20134","journal-title":"Neuroscience."},{"key":"1637_CR41","doi-asserted-by":"publisher","first-page":"PL1","DOI":"10.1016\/S0024-3205(98)00238-0","volume":"63","author":"F Petitet","year":"1998","unstructured":"Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1\u2013PL6","journal-title":"Life Sci"},{"key":"1637_CR42","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1046\/j.0022-3042.2001.00716.x","volume":"80","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448\u2013456","journal-title":"J Neurochem"},{"key":"1637_CR43","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","volume":"30","author":"AA Izzo","year":"2009","unstructured":"Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515\u2013527","journal-title":"Trends Pharmacol Sci"},{"key":"1637_CR44","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","volume":"134","author":"T Bisogno","year":"2001","unstructured":"Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB et al (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845\u2013852","journal-title":"Br J Pharmacol"},{"key":"1637_CR45","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037\u20131043","journal-title":"Neurochem Res"},{"key":"1637_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2202-11-44","volume":"11","author":"D McHugh","year":"2010","unstructured":"McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z (2010) Walker JM, and Bradshaw HB N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11:44","journal-title":"BMC Neurosci"},{"key":"1637_CR47","doi-asserted-by":"crossref","unstructured":"Cascio MG, Gauson LA, Stevenson LA, Ross RA, and Pertwee RG Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 2010;159:129\u2013141.","DOI":"10.1111\/j.1476-5381.2009.00515.x"},{"key":"1637_CR48","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bph.12321","volume":"170","author":"TD Hill","year":"2013","unstructured":"Hill TD, Cascio MG, Romano B, Duncan N, Pertwee RG, Williams CM, Whalley BJ, Hill AJ (2013) Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 170:679\u2013692","journal-title":"Br J Pharmacol"},{"key":"1637_CR49","doi-asserted-by":"crossref","unstructured":"Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, and Pertwee RG Evidence that the plant cannabinoid Delta-9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor agonist. Br J Pharmacol 2005;146:917\u2013926.","DOI":"10.1038\/sj.bjp.0706414"},{"key":"1637_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/7854_2016_60","volume":"32","author":"S Tai","year":"2017","unstructured":"Tai S, Fantegrossi WE (2017) Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites. Curr Top Behav Neurosci 32:249\u2013262","journal-title":"Curr Top Behav Neurosci"},{"key":"1637_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fphar.2017.00020","volume":"8","author":"G Watt","year":"2017","unstructured":"Watt G, Karl T (2017) In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer\u2019s disease. Front Pharmacol 8:20","journal-title":"Front Pharmacol"},{"key":"1637_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/112_2017_3","volume":"173","author":"BM Fonseca","year":"2017","unstructured":"Fonseca BM, Teixeira NA, Correia-da-Silva G (2017) Cannabinoids as modulators of cell death: clinical applications and future directions. Rev Physiol Biochem Pharmacol 173:63\u201388","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"1637_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neuro.2011.12.015","volume":"33","author":"BS Harvey","year":"2012","unstructured":"Harvey BS, Ohlsson KS, Maag JL, Musgrave IF, Smid SD (2012) Contrasting protective effects of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro. Neurotoxicology. 33:138\u2013146","journal-title":"Neurotoxicology."},{"key":"1637_CR54","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","volume":"151","author":"G Esposito","year":"2007","unstructured":"Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D, Cottone P, Iuvone T, Cuomo V et al (2007) Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 151:1272\u20131279","journal-title":"Br J Pharmacol"},{"key":"1637_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028668","volume":"6","author":"G Esposito","year":"2011","unstructured":"Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratu MR et al (2011) Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS One 6:e28668","journal-title":"PLoS One"},{"key":"1637_CR56","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s00213-014-3478-5","volume":"231","author":"D Cheng","year":"2014","unstructured":"Cheng D, Low JK, Logge W, Garner B, Karl T (2014) Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe\/PS1E9 mice. Psychopharmacology 231:3009\u20133017","journal-title":"Psychopharmacology"},{"key":"1637_CR57","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3233\/JAD-140921","volume":"42","author":"D Cheng","year":"2014","unstructured":"Cheng D, Spiro AS, Jenner AM, Garner B, Karl T (2014) Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice. J Alzheimers Dis 42:1383\u20131396","journal-title":"J Alzheimers Dis"},{"key":"1637_CR58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JAD-130050","volume":"35","author":"MJ Casarejos","year":"2013","unstructured":"Casarejos MJ, Perucho J, Gomez A, Munoz MP, Fernandez-Estevez M, Sagredo O, Fernandez Ruiz J, Guzman M et al (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35:525\u2013539","journal-title":"J Alzheimers Dis"},{"key":"1637_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fphar.2014.00037","volume":"5","author":"E Aso","year":"2014","unstructured":"Aso E, Ferrer I (2014) Cannabinoids for treatment of Alzheimer\u2019s disease: moving toward the clinic. Front Pharmacol 5:37","journal-title":"Front Pharmacol"},{"key":"1637_CR60","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3233\/JAD-141014","volume":"43","author":"E Aso","year":"2015","unstructured":"Aso E, Sanchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I (2015) Cannabis-based medicine reduces multiple pathological processes in AbetaPP\/PS1 mice. J Alzheimers Dis 43:977\u2013991","journal-title":"J Alzheimers Dis"},{"key":"1637_CR61","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1211\/jpp.59.12.0010","volume":"59","author":"MC Foti","year":"2007","unstructured":"Foti MC (2007) Antioxidant properties of phenols. J Pharm Pharmacol 59:1673\u20131685","journal-title":"J Pharm Pharmacol"},{"key":"1637_CR62","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget. 8:38022\u201338043","journal-title":"Oncotarget."},{"key":"1637_CR63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/17512433.2014.910111","volume":"7","author":"C Tannenbaum","year":"2014","unstructured":"Tannenbaum C, Sheehan NL (2014) Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol 7:533\u2013544","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-1637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-019-1637-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-1637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T15:32:20Z","timestamp":1650468740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-019-1637-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,19]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s12035-019-1637-8","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,19]]},"assertion":[{"value":"30 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All of the cell lines used in the screening assays are available. All data generated or analyzed during this study are included in the manuscript or available upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}